JY
AUTL

Jeff Yass’s Autolus Therapeutics AUTL Stock Holding History

Jeff Yass’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$19.9K – 13139
2025
Q4 		$19.9K Sell
10,000
-6,600
-40% -$10.1K ﹤0.01% 11960
2025
Q3 		$27.1K Buy
16,600
+6,000
+57% +$11.7K ﹤0.01% 11999
2025
Q2 		$24.2K Sell
10,600
-1,800
-15% -$2.98K ﹤0.01% 12296
2025
Q1 		$19.2K Sell
12,400
-76,700
-86% -$156K ﹤0.01% 12119
2024
Q4 		$209K Buy
89,100
+76,500
+607% +$259K ﹤0.01% 10637
2024
Q3 		$45.7K Sell
12,600
-4,000
-24% -$16K ﹤0.01% 11416
2024
Q2 		$57.8K Sell
16,600
-43,400
-72% -$187K ﹤0.01% 11347
2024
Q1 		$383K Buy
+60,000
New +$374K ﹤0.01% 9130
2022
Q1 		– Sell
-22,200
Closed -$115K – 12945
2021
Q4 		$115K Sell
22,200
-34,600
-61% -$208K ﹤0.01% 12036
2021
Q3 		$372K Buy
+56,800
New +$359K ﹤0.01% 10093

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jeff Yass's AUTL Position: Q2 2026 in Review

Jeff Yass reduced its Autolus Therapeutics (AUTL) stake by 56% in Q2 2026, selling an estimated $348K and leaving 177,232 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #11177.

Jeff Yass first reported a position in AUTL in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.19M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Jeff Yass held 177,232 shares of Autolus Therapeutics worth $284K as of Q2 2026.
  • Jeff Yass sold 221,911 Autolus Therapeutics shares in Q2 2026, an estimated $348K.
  • Autolus Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11177 holding.
  • Jeff Yass first reported a position in Autolus Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Jeff Yass's Autolus Therapeutics position peaked at $1.19M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.